The largest database of trusted experimental protocols

Taurocholic Acid

Taurocholic acid is a bile acid conjugated with the amino acid taurine.
It is synthesized in the liver and plays a key role in the digestion and absorption of fats.
Taurocholic acid helps solubilize lipids, enabling their transport and uptake in the intestines.
It also has antimicrobial properties and may influence the gut microbiome.
Researchs on taurocholic acid's physiological functions and potential therapeutic applications are ongoing.
Optimizing experimental protocols and product selection is crucial for enhancing reproducibility in this field of study.

Most cited protocols related to «Taurocholic Acid»

Fecal samples from three healthy individuals were collected into sterile containers, sealed, and transferred to an anaerobic chamber within 1 h of defecation. Samples were manually homogenized and subdivided into sterile vials, which were stored at −80 °C until use. Prior to MBRA inoculation, fecal samples were resuspended at 25 % w/v in anaerobic phosphate buffered saline in the anaerobic chamber, vortexed for 5 min, and centrifuged at 201×g. For the pooled sample, equal amounts of each fecal sample (by mass) were combined prior to vortexing.
In order to analyze the impact of freezing upon MBRA cultivation, one fecal donor (donor A) provided a second sample ~3 months post initial donation (donor A2). This sample was collected and transferred to the anaerobic chamber within 1 h of defecation. Following manual homogenization and subdivision into sterile vials, a portion of the sample was flash frozen in liquid nitrogen for 45 min (frozen), whereas the other sample was maintained in the anaerobic chamber until inoculation. Both fresh and frozen samples were then inoculated into triplicate reactors and analyzed as described below. Analysis of this data revealed that there was little impact on communities cultivated from frozen samples compared to freshly voided samples (see Additional file 11 for an NMDS ordination of the Bray-Curtis dissimilarities between these different samples as well tests of community similarity and dispersion).
MBRA were prepared for use as previously described [29 (link)] and inoculated with 4 ml of fecal slurry. Bioreactor medium was prepared as described [29 (link)], except that 1 g/L of taurocholic acid was replaced with 0.5 g/L of bovine bile, which was added prior to autoclaving. There were multiple reasons for substituting bovine bile for taurocholate. (1) Bovine bile is a complex mixture of bile salts as well as other constituents of bile (e.g., fatty acids, cholesterol, inorganic salts) and is more commonly used in medium for cultivation of human fecal communities than taurocholate alone. (2) Taurocholate was originally included in our medium to promote germination of C. difficile spores; subsequent studies have shown that bovine bile is sufficient to support germination under our reactor conditions (Auchtung and Britton, unpublished results). (3) Bovine bile is significantly less expensive than taurocholate (>10-fold lower cost).
After inoculation, fecal bacteria were allowed to equilibrate for 16–18 h prior to the initiation of flow. After equilibration, a 1-ml sample was removed (day 1 sample) and flow commenced at 1.875 ml/h (8-h retention time). Reactors were then sampled daily for 20 additional days (days 2–21). Cells were pelleted from samples by centrifugation at 21,000×g. Supernatants were discarded, and pellets were stored at −80 °C until further processed.
Full text: Click here
Publication 2015
Bacteria Bile Bioreactors Cattle Cells Centrifugation Cholesterol Complex Mixtures Defecation Fatty Acids Feces Freezing Germination Homo sapiens Nitrogen Nonsense Mediated mRNA Decay Pellets, Drug Phosphates Retention (Psychology) Saline Solution Salts Salts, Bile Spores Sterility, Reproductive Taurocholate Taurocholic Acid Tissue Donors Vaccination
For BA analysis, samples (≈40 mg of caecal content) were homogenised with acetonitrile using zirconia/silica beads (0.1 mm diameter). After discarding stool particles, the supernatant was evaporated in a vacuum centrifuge and solubilised in a volume of methanol to a final concentration of 1 μL mg−1 of gut content. Chromatographic separation was performed on Agilent 1290 Infinity UHPLC using a 150 mm × 2.1 mm internal diameter (i.d.) Phenomenex Kinetex® C18 core-shell column, packed with 2.6-μm particles. HPLC was carried out with mobile phase A (0.1% formic acid in aqueous solution) and mobile phase B (0.1% formic acid in acetonitrile) at a total flow rate of 0.5 mL min−1. Gradient program was increased linearly from 5% mobile phase B and 95% mobile phase A to 100% mobile phase B for 9.5 min. Bile acid identities were established in negative ion mode using a mass MSMS instrument (Agilent QTOF 6540) and the following pure standards: cholic acid (C1129, SIGMA), deoxycholic acid (D4297, SIGMA), lithocholic acid (L6250, SIGMA), chenodeoxycholic acid (C1050000, European Pharmacopoeia Reference Standard), cholic acid 7-sulphate (9002532, Cayman Chemical), α-muricholic acid (C1890-000, Steraloids), β-muricholic acid (sc-477731, Santa Cruz), ω-muricholic acid (C1888-000, Steraloids), ursodeoxycholic acid (C1020-000, Steraloids), hyodeoxycholic acid (H0535, TCI), taurocholic acid (sc-220189, Santa Cruz) and taurodeoxycholic acid (15935, Cayman Chemical). Peak integration and analysis was performed using ProFinder (software version B.06.00, Agilent Technologies) and a customised spectral library.
For SCFA profiling, samples were spiked with 5 nmol of 13C-sodium acetate (279293, SIGMA) and 5 nmol of 2-ethyl butyric acid (109959, SIGMA) as internal standards and were homogenised in isopropanol. After centrifugation, 1 μL of the supernatant was injected into a HP 6890 Series GC System, equipped with an Agilent 5973 Network Mass Selective Detector in splitless mode. Samples were separated on a Stabilwax®-DA (Shimadzu) column (30 m × 0.25 mm i.d.) coated with a 0.25-μm-thick film. The carrier gas was helium at a flow rate of 1 mL min−1. The initial oven temperature of 90 °C was held for 2 min, then increased to 240 °C at 5 °C min−1 and maintained for additional 2 min. The temperature of the quadrupole, MS source and inlet were 150, 230 and 250 °C, respectively. Identities and retention times of the SCFA were established using the volatile-free acid mix (46975-U, Supelco). Peaks were automatically integrated using MSD ChemStation (version D.03.00.611). SCFA concentration was estimated using the internal references 13C-sodium acetate (for acetic acid) or 2-ethyl butyric acid (for all the others SCFA tested). Data were calculated as nanomoles per microlitre serum or per milligram caecal content from at least three biological replicates within each different group.
Full text: Click here
Publication 2017
Acetic Acid acetonitrile Acids ARID1A protein, human Bile Acids Biopharmaceuticals Butyric Acid Caimans cDNA Library Cecum Centrifugation Chenodeoxycholic Acid Cholic Acid Chromatography Deoxycholic Acid Europeans Feces formic acid Helium High-Performance Liquid Chromatographies hyodeoxycholic acid Isopropyl Alcohol Lithocholic Acid Methanol muricholic acid Retention (Psychology) Serum Silicon Dioxide Sodium Acetate Sulfates, Inorganic Taurocholic Acid Taurodeoxycholic Acid Ursodiol Vacuum zirconium oxide
More detailed information about quantification of BAs, hepatocyte culture and taurocholic acid (TCA) uptake in vitro, BA dynamics in vivo, Myrcludex imaging, and the methods described below is provided in the Supporting Information.
Full text: Click here
Publication 2015
NOS2A protein, human Taurocholic Acid

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Acids Bile Acids Cells Gastroesophageal Reflux Disease Glycochenodeoxycholic Acid Glycocholic Acid Glycodeoxycholic Acid Molar Salts, Bile Taurochenodeoxycholic Acid Taurocholic Acid Taurodeoxycholic Acid
During the sample preparation, lipids and polar metabolites were separated prior to analyses through solvent extraction/fractionation. Hence, potential problems in ion suppression or the ability of compounds to be ionized were limited due to the use of Lipidomic LC–MS/MS, HILIC-MS/MS (including positive and negative electrospray), and the complementary use of GC-electron ionization-MS.
Briefly, five milligrams of tissue from each brain region were homogenized in 225 µL of −20 °C cold, internal standard-containing methanol using a GenoGrinder 2010 (SPEX SamplePrep) for 2 min at 1,350 rpm. The extraction methanol contained the following internal standards for quality control and retention time normalization: sphingosine (d17:1), LPE (17:1), LPC (17:0), MG (17:0/0:0/0:0), DG (12:0/12:0/0:0), PC (12:0/13:0), cholesterol-d7, SM (18:1/17:1), ceramide (d18:1/17:0), PE (17:0/17:0), TG (14:0/16:1/14:0)-d5, TG (17:0/17:1/17:0)-d5, acylcarnitine (18:1)-d3, fatty acid (16:0)-d3, MAG (17:0/0:0/0:0), PI (15:0–18:1)-d7, PG (17:0/17:0), PS (15:0-18:1)-d7, glucosylceramide(d18:1/17:0), mono-sulfo galactosylceramide(d18:1/17:0), and 5-PAHSA-d9. The homogenate was vortexed for 10 s. 750 µL of −20 °C cold, internal standard-containing methyl tertiary-butyl ether (MTBE) was added, and the mixture was vortexed for 10 s and shaken at 4 °C for 5 min with an Orbital Mixing Chilling/Heating Plate (Torrey Pines Scientific Instruments). MTBE contained cholesteryl ester 22:1 as internal standard. Next, 188 µL room temperature water was added and vortexed for 20 s to induce phase separation. After centrifugation for 2 min at 14,000×g, two 350 µL aliquots of the upper non-polar phase and two 125 µL aliquots of the bottom polar phase were collected and dried down. The remaining fractions were combined to form QC pools and were injected after every set of 10 biological samples.
The non-polar phase employed for lipidomics was resuspended in a mixture of methanol/toluene (60 µL, 9:1, v/v) containing an internal standard [12-[(cyclohexylamine) carbonyl]amino]-dodecanoic acid (CUDA)] before injection. Resuspension of dried polar phases for HILIC analysis was performed in a mixture of acetonitrile/water (90 µL, 4:1, v/v) containing the following internal standards: CUDA, caffeine-d9, acetylcholine-d4, TMAO-d9, 1-methylnicotinamide-d3, Val-Tyr-Val, betaine-d9, acyl carnitine (2:0)-d3, N-methyl-histamine-d3, l-carnitine-d3, butyrobetaine-d9, l-glutamine-d5, aspartic acid-d3, l-arginine-15N2, cystine-d4, asparagine-d3, histidine-d5, isoleucine-d10, leucine-d10, methionine-d8, ornithine-d2, phenylalanine-d8, proline-d7, threonine-d5, tryptohan-d8, tyrosine-d7, valine-d8, spermine-d8, glucose-d7, fructose-6-phosphate-13C6, succinic acid-d4, taurocholic acid-d4, adenosine 5′-monophosphate-15N5, uridine 5′-monophosphate-15N2, dopamine-d4, taurine-d4, uracil-d2, biotin-d4, N-acetylalanine-d3, guanine-13C, and adenosine-13C5. The second dried polar phase was reserved for GC analysis and a following derivatization process was carried out before injection. First, carbonyl groups were protected by methoximation with methoxyamine hydrochloride in pyridine (40 mg/mL, 10 µL) was added to the dried samples. Then, the mixture was incubated at 30 °C for 90 min followed by trimethylsilylation with N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA, 90 μL) containing C8–C30 fatty acid methyl esters (FAMEs) as internal standards by shaking at 37 °C for 30 min.
Full text: Click here
Publication 2021
5-PAHSA acetonitrile Acetylcholine acylcarnitine Adenosine Adenosine Monophosphate Amino Acids Arginine Asparagine Aspartic Acid Betaine Biopharmaceuticals Biotin Brain Caffeine Centrifugation Ceramides Cholesterol Cholesterol Esters Cold Temperature Cyclohexylamines Cystine Dopamine Electrons Esters Ethyl Ether Fatty Acids Fractionation, Chemical fructose-6-phosphate Galactosylceramides gamma-butyrobetaine Gas Chromatography-Mass Spectrometry Glucose Glucosylceramides Glutamine Guanine Histidine Isoleucine Leucine Levocarnitine Lipids Methanol Methionine methoxyamine methoxyamine hydrochloride Methylhistamines N(1)-methylnicotinamide N-acetylalanine N-methyl-N-(trimethylsilyl)trifluoroacetamide Ornithine PC 12 ester Phenylalanine Pinus Proline PS 15 pyridine pyridine hydrochloride Retention (Psychology) Solvents Spermine Sphingosine Succinic Acid Tandem Mass Spectrometry Taurine Taurocholic Acid Threonine Tissues Toluene trifluoroacetamide trimethyloxamine Tyrosine Uracil Uridine Monophosphate Valine valylvaline

Most recents protocols related to «Taurocholic Acid»

BAs in plasma, feces, and liver tissue were measured. Detailed analytical methods are provided in the Supplementary Materials. BAs were quantified using ultraperformance liquid chromatography coupled to tandem mass spectrometry (UPLC‐MS/MS) in combination with multiple reactions monitoring methods on the ACQUITY UPLC system (Waters). All calibration standard solutions were mixed at appropriate concentrations and analyzed every 10 samples for quality control.
BAs were divided into four groups according to the degree of conjugation,8 including (a) unconjugated PBAs: UDCA, α MCA, β MCA, CA, and CDCA; (b) conjugated PBAs: tauroursodeoxycholic acid (TUDCA), tauro‐β‐muricholic acid (T‐β‐MCA), tauro‐α‐muricholic acid (T‐α‐MCA), glycochenodeoxycholic acid (GCDCA), taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), and taurocholic acid (TCA); (c) unconjugated SBAs: DCA, LCA, hyocholic acid (HCA), and ω MCA; and (d) conjugated SBAs: taurolithocholic acid (TLCA), taurohyocholic acid (THCA), taurodeoxycholic acid (TDCA), and tauro‐ω‐muricholic acid (T‐ω‐MCA).
Full text: Click here
Publication 2023
4-phenylbutyric acid Acids Chenodeoxycholic Acid Feces Glycochenodeoxycholic Acid Glycocholic Acid hyocholic acid Liquid Chromatography Liver muricholic acid Plasma Tandem Mass Spectrometry Taurochenodeoxycholic Acid Taurocholic Acid Taurodeoxycholic Acid Taurolithocholic Acid tauroursodeoxycholic acid Tissues Ursodiol
Female and male C57BL6/J mice were immunized with MOG as described above. Daily gavage of either 100 μL of 125 mg/mL taurocholic acid (in saline) or 100 μL of saline started on day 4 and continued through day 10. Mice were then monitored and scored as described earlier.
Full text: Click here
Publication 2023
Females Males Mice, House Saline Solution Taurocholic Acid Tube Feeding
Bacterial seed cultures were inoculated into 2 ml PPS medium, which contained the taurine-conjugated bile acid mixture (5 μM each) of taurocholic acid (TCA, Millipore Sigma, #86339), TβMCA (Cayman, #20289), taurochenodeoxycholic acid (TCDCA, Millipore Sigma, #T6260), THDCA (Millipore Sigma, #T0682), taurodeoxycholic acid (TDCA, Millipore Sigma, #T0875) and taurolithocholic acid (TLCA, Millipore Sigma, #T7515). These cultures were then grown overnight anaerobically at 37 °C. The entire culture was subjected to the bile acid measurement. To verify the inhibitory effects of BSH inhibitor, 10 μM C7 was added to the culture medium during inoculation. Hydrolysis efficacy was determined by the percentage of remaining conjugated bile acids in the bacterial culture medium, which was normalized with blank controls defined as 100%.
Full text: Click here
Publication 2023
Bacteria Bile Acids Caimans Culture Media Hydrolysis Psychological Inhibition Taurine Taurochenodeoxycholic Acid Taurocholic Acid Taurodeoxycholic Acid taurohyodeoxycholic acid Taurolithocholic Acid Vaccination
4-Acetamidophenol (acetaminophen, APAP, 98%), cholic acid (CA), chenodeoxycholic acid (CDCA), glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), deoxycholic acid (DCA), lithocholic acid (LCA), taurocholic acid (TCA), taurodeoxycholic acid (TDCA), taurolithocholic acid (TLCA), ursodeoxycholic acid (UDCA), uridine-5′-diphosphoglucuronic acid (UDPGA), 3′-phosphoadenosine-5′-phosphosulfate (PAPS), nicotinamide adenine dinucleotide phosphate (NADP+), glucose-6-phosphate, MgCl2, glucose-6-phosphate dehydrogenase, acetonitrile (ACN), and methanol (MeOH) (both HPLC grade) as well as formic acid (LC-MS grade) were all purchased from Sigma-Aldrich (Oakville, ON, Canada). Rat (Sprague−Dawley) liver microsomes (RLM, part #452501) and S9 hepatic fractions (RS9, part #452591) were purchased from Corning (Corning, NY, USA). Ultrapure water was from a Millipore Synergy UV system (Billerica, MA, USA). MetaboloMetricsTM bile acid analysis kits contained a standard mix of 46 bile acids and 14 deuterated isotope-labeled internal standards and were obtained from MRM Proteomics Inc. (Montreal, QC, Canada). Sprague Dawley rats were treated by intraperitoneal injection with 75, 150, 300, and 600 mg/kg APAP in triplicate. Rat plasma was collected after 24 h at the INRS Centre de Biologie Expérimentale (Laval, QC, Canada), within standard ethical practices of the Canadian Council on Animal Care (project UQLK.14.02). These samples were collected in February 2014 and stored at −80 °C until proceeding with sample preparation.
A standard mix of 46 bile acids was provided as a dried sample (tube A). Bile acids were present at a concentration of 2.5 nmol, except for deoxycholic acid (DCA) at 5 nmol and taurohyocholic acid (THCA) at 6.5 nmol. The bile acids in the standard mix were as follows: 12-ketodeoxycholic acid (12-keto-DCA), 12-ketolithocholic acid (12-keto-LCA), 3-dehydrocholic acid (3-DHCA), 7-ketodeoxycholic acid (7-keto-DCA), 7-ketolithocholic acid (7-keto-LCA), allocholic acid (ACA), alloisolithocholic acid (AILCA), apocholic acid (APCA), chenodeoxycholic acid (CDCA), cholic acid (CA), dehydrocholic acid (DHCA), deoxycholic acid (DCA), dioxolithocholic acid (di-oxo-LCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), glycohyocholic acid (GHCA), glycohyodeoxycholic acid (GHDCA), glycolithocholic acid (GLCA), glycoursodeoxycholic acid (GUDCA), hyodeoxycholic acid (HDCA), isodeoxycholic acid (IDCA), isolithocholic acid (ILCA), lithocholic acid (LCA), murocholic acid (muro-CA), norcholic acid (NCA), nordeoxycholic acid (NDCA), norursodeoxycholic acid (NUDCA), tauro-α-muricholic acid (α-TMCA), tauro-β-muricholic acid (β-TMCA), tauro-ω-muricholic acid (ω-TMCA), taurochenodeoxycholic acid (TCDCA), taurocholic acid (TCA), taurodehydrocholic acid (TDHCA), taurodeoxycholic acid (TDCA), taurohyocholic acid (THCA), taurolithocholic acid (TLCA), tauroursodeoxycholic acid (TUDCA), ursocholic acid (UCA), ursodeoxycholic acid (UDCA), α-muricholic acid (α-MCA), β-muricholic acid (β-MCA), ω-muricholic acid (ω-MCA), 6,7-diketolithocholic acid (6,7-diketo-LCA), dehydrolithocholic acid (DHLCA), and glycodehydrocholic acid (GDHCA).
A mix of isotopically labeled bile acids (0.1–0.75 nmol) was provided as a dried sample (tube B) and was used as internal standard for data normalization. The labeled bile acids in the internal standard mix were as follows: glycoursodeoxycholic acid-d4 (d4-GUDCA), glycocholic acid-d4 (d4-GCA), tauroursodeoxycholic acid-d4 (d4-TUDCA), taurocholic acid-d4 (d4-TCA), cholic acid-d4 (d4-CA), ursodeoxycholic acid-d4 (d4-UDCA), glycochenodeoxycholic acid-d4 (d4-GCDCA), glycodeoxycholic acid-d4 (d4-GDCA), taurochenodeoxycholic acid-d4 (d4-TCDCA), taurodeoxycholic acid-d6 (d6-TDCA), chenodeoxycholic acid-d4 (d4-CDCA), deoxycholic acid-d4 (d4-DCA), glycolithocholic acid-d4 (d4-GLCA), and lithocholic acid-d4 (d4-LCA).
Full text: Click here
Publication 2023
3-oxocholan-24-oic acid 7-ketodeoxycholic acid 7-ketolithocholic acid 12-ketolithocholic acid Acetaminophen acetonitrile Acids ACPP protein, human allocholic acid Animals Bile Acids Chenodeoxycholic Acid Cholic Acid Dehydrocholic Acid Deoxycholic Acid formic acid Glucose-6-Phosphate Glucosephosphate Dehydrogenase Glycochenodeoxycholic Acid Glycocholic Acid Glycodeoxycholic Acid glycohyodeoxycholic acid glycolithocholic acid glycoursodeoxycholic acid High-Performance Liquid Chromatographies hyodeoxycholic acid Injections, Intraperitoneal International Normalized Ratio Isotopes Keto Acids Lithocholic Acid Magnesium Chloride Methanol Microsomes, Liver muricholic acid NADP norcholic acid Phosphoadenosine Phosphosulfate Plasma Rats, Sprague-Dawley Taurochenodeoxycholic Acid Taurocholic Acid Taurodeoxycholic Acid Taurolithocholic Acid tauroursodeoxycholic acid trimethylcolchicinic acid Uridine Diphosphate Glucuronic Acid ursocholic acid Ursodiol
The ex vivio perfusion circuit was composed of a centrifugal pump (Rotaflow centrifugal pump), 2 hard shell reservoirs (Maquet, Hirrlingen, Germany), a leukocyte filter and a hollow-fiber dialyzer (NR16, Fresenius, Bad Homburg, Germany). The setup was similar to the OrganOx Metra that has recently been published in human clinical trials and has been described previously [46 (link),47 (link),48 (link)]. The hepatic artery pressure was set to 50–60 mm Hg, resulting in a flow of up to 400 mL/h. A second reservoir was used to regulate the portal vein pressure, which was intended to reach 2–4 mm Hg and a flow of 900–1400 mL/h. Porcine blood was obtained from the donor animal shortly before liver retrieval and erythrocytes were passed through leukocyte filters. For the perfusate, 1.5 L of Steen Solution (XVIVO Perfusion, Goteborg, Sweden) was mixed with the washed porcine erythrocytes (around 400 g) to achieve a final hematocrit of 15% with a hemoglobin level of 45 mg/dL. During the priming of the circuit, Heparin (10,000 international units (IU), Sandoz Canada, Quebec, QC, Canada), amino acid concentrate (Travasol 4.25%, 50 mL Bolus, Baxter, Hamilton, ON, Canada), sodium bicarbonate (20 mmol), calcium chloride (9.2 mmol/L) and antibiotics (Cefazolin—1 g, Pharmaceutical Partners of Canada, Richmond Hill, ON, Canada and Metronidazole—500 mg, Baxter, Mississauga, ON, Canada) were added. Additionally, amino acid concentrate (Travasol 4.25%, 8 mL/h, Baxter, Hamilton, ON, Canada), insulin (125 IU/h, NovoRapid, Novo Nordisk, Mississauga, ON, Canada), 2% taurocholic acid (7 mL/h, Sigma-Aldrich, St. Louis, MO, USA infused as a precursor for bile production) and prostaglandin E1 (500 μg/3 h, Pfizer, Kirkland, QC, Canada) were continuously administered during the perfusion. The surgical protocol for the donor liver retrieval and the liver transplantation has been described in more detail previously [24 (link),44 (link),45 (link)].
Full text: Click here
Publication 2023
Alprostadil Amino Acids Animals Antibiotics Arteries Bicarbonate, Sodium Bile BLOOD Calcium chloride Cefazolin Donors Erythrocytes Fibrosis Hemoglobin A Heparin Hepatic Artery Homo sapiens Insulin Leukocytes Liver Liver Transplantations Metronidazole NovoLog Operative Surgical Procedures Perfusion Pharmaceutical Preparations Pigs Portal Pressure Pressure Taurocholic Acid Travasol Volumes, Packed Erythrocyte

Top products related to «Taurocholic Acid»

Sourced in United States, United Kingdom, Switzerland, Germany, Sao Tome and Principe
Taurocholic acid is a bile acid that functions as a surfactant, facilitating the digestion and absorption of fats in the small intestine. It is a key component in the bile produced by the liver and plays a role in the emulsification and solubilization of lipids.
Sourced in United States, United Kingdom, Switzerland, Canada, Ireland
Taurodeoxycholic acid is a bile acid compound that is commonly used as a laboratory reagent. It serves as a solubilizing agent and is employed in various biochemical and cell culture applications.
Sourced in United States, Germany, United Kingdom, Switzerland
Taurochenodeoxycholic acid is a laboratory reagent used in biochemical research. It is a bile acid derivative that serves as a fundamental component in various analytical and experimental procedures. The core function of taurochenodeoxycholic acid is to facilitate specific chemical reactions and analyses in a controlled laboratory environment, though its precise applications may vary depending on the research context.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Switzerland, Canada, Japan, Macao, New Zealand, China
Cholic acid is a natural bile acid found in the human body. It is used as a basic laboratory compound for various research and analytical purposes.
Sourced in United States, Germany, Switzerland, France, United Kingdom, Canada, Belgium
Chenodeoxycholic acid is a naturally occurring bile acid. It is a key component in the biosynthesis of bile salts and is involved in the regulation of cholesterol levels in the body.
Sourced in United States, United Kingdom, Switzerland
Glycodeoxycholic acid is a bile acid that can be used as a laboratory reagent. It is a naturally occurring compound found in bile.
Sourced in United States, Switzerland, United Kingdom, Germany
Glycocholic acid is a bile acid found in the human body. It is a crystalline compound that is used as a laboratory reagent in various biochemical and analytical applications.
Sourced in United States, United Kingdom, Belgium
Glycochenodeoxycholic acid is a bile acid compound used in various laboratory applications. It serves as a key component in research and analysis processes, particularly in the study of biological and biochemical systems. The compound has well-defined chemical properties and functions that make it a valuable tool for scientific investigations.
Sourced in United States, Germany, United Kingdom, Switzerland, Belgium, China, Canada, France
Deoxycholic acid is a bile acid that is commonly used in laboratory settings. It is a white, crystalline powder with a molecular formula of C₂₄H₄₀O₄. Deoxycholic acid functions as a surfactant and is often utilized in various biochemical and cell biology applications.
Sourced in United States, United Kingdom, Germany, Switzerland
Ursodeoxycholic acid is a chemical compound that is used as a pharmaceutical ingredient in various medical products. It is a naturally occurring bile acid that can be synthesized for use in laboratory and medical applications. The core function of ursodeoxycholic acid is to act as a bile acid and assist in the regulation of bile production and metabolism.

More about "Taurocholic Acid"

Taurocholic acid, also known as taurocholate or cholic acid conjugate, is a bile acid that plays a crucial role in the digestion and absorption of fats.
Synthesized in the liver, this bile salt helps solubilize lipids, enabling their transport and uptake in the intestines.
Taurocholic acid is one of the primary bile acids, along with other conjugates like taurodeoxycholic acid (TDCA), taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), and glycochenodeoxycholic acid (GCDCA).
Bile acids, including taurocholic acid, have antimicrobial properties and can influence the gut microbiome.
They are involved in the regulation of lipid and glucose metabolism, and research is ongoing to explore their potential therapeutic applications.
Optimizing experimental protocols and product selection is crucial for enhancing reproducibility in taurocholic acid research.
Researchers can leverage AI-powered tools like PubCompare.ai to easily locate protocols from literature, preprints, and patents, and compare them to identify the best approaches.
By utilizing these cutting-edge tools, researchers can optimize their workflows and experience enhanced reproducibility in their studies on taurocholic acid and related bile acids.